[Federal Register Volume 63, Number 225 (Monday, November 23, 1998)]
[Notices]
[Page 64723]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-31269]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Dental Plaque Subcommittee of the Nonprescription Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting is
open to the public.
Name of Committee: Dental Plaque Subcommittee of the
Nonprescription Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 2 and 3, 1998,
8:30 a.m. to 5 p.m.
Location: Advisory Committee Conference Room 1066, 5630 Fishers
Lane, Rockville, MD.
Contact Person: Robert L. Sherman or Stephanie A. Mason, Center for
Drug Evaluation and Research (HFD-560), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-827-5191, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 12541. Please call the Information Line for
up-to-date information on this meeting.
Agenda: On December 2, 1998, the subcommittee will: (1) Review the
ingredients triclosan and the combination of triclosan and zinc
citrate; (2) review and vote on the combination of zinc chloride,
sodium citrate, hydrogen peroxide, and sodium lauryl sulfate; and (3)
discuss comments on the draft subcommittee report. On December 3, 1998,
the subcommittee will discuss comments on the draft report and adopt
the report.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by November 25,
1998. Oral presentations from the public will be scheduled between
approximately 8:30 a.m. and 12 m. Time allotted for each presentation
may be limited. Those desiring to make formal oral presentations should
notify the contact person before November 25, 1998, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their
presentation.
FDA regrets that it was unable to publish this notice 15 days prior
to the Dental Plaque Subcommittee of the Nonprescription Drugs Advisory
Committee meeting. Because the agency believes there is some urgency to
bring these issues to public discussion and qualified members of the
Dental Plaque Subcommittee of the Nonprescription Drugs Advisory
Committee were available at this time, the Commissioner concluded that
it was in the public interest to hold this meeting even if there was
not sufficient time for the customary 15-day public notice.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: November 16, 1998.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 98-31269 Filed 11-20-98; 8:45 am]
BILLING CODE 4160-01-F
